RNXT
RenovoRx, Inc.
Healthcare — Biotechnology
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
None
4 analysts
$1.55
$-0.01 (-0.64%)
Target:
$7.03
(353.5%)
Price History
52-Week Range
Sign in to add RNXT to a watchlist or set price alerts.
Fundamentals
| Market Cap | $43.08M |
| P/E Ratio (TTM) | - |
| Forward P/E | -6.37 |
| EPS (TTM) | $-0.33 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 185.80% |
| ROE | -100.48% |
| Debt/Equity | 1.65 |
| Recommendation | None |
| Analyst Target | $7.03 |
| Analysts | 4 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 69.0 |
| Beta | 1.00 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $1.45 |
| 52-Week Low | $0.70 |
| 50-Day Avg | $0.89 |
| 200-Day Avg | $0.98 |
| Avg Volume | 294.1K |
| Volume | 173.4K |
Performance Analysis
BULLISHRNXT shows predominantly bullish signals based on its fundamentals and technicals.
-
Trading near its 52-week high ($1.45), which may indicate limited upside.
+
RSI at 69.0 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Strong revenue growth of 185.8% year-over-year.
~
Wall Street consensus is "none" from 4 analysts.
+
Average analyst target of $7.03 implies 353.5% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:29 UTC
Back to Screener Export Report